Shield Therapeutics lifts H1 revenue 42% as it stays on track for 2026 profitability
Shield Therapeutics reports stronger first-half sales and a sharply narrower loss for the six months ended June 30, 2026, as demand for its iron deficiency treatment ACCRUFeR continues to grow in the U.S. The company says group revenue reaches $30.4 million, while cash and cash equivalents stand at $8.3 million at the end of the period.
Highlights
- Shield Therapeutics' group revenue grew 42% year-on-year to $30.4 million in H1 2026, narrowing its loss to $2.3 million from $9.5 million.
- ACCRUFeR revenue rose 5% to $20.1 million with 102,000 prescriptions sold in H1 2026, up from 84,000 in H1 2025, supporting U.S. commercialization momentum.
- Shield remains on track for 2026 operating profitability as patient indication extensions in the U.S. and Europe drive milestone payments and royalties, diversifying revenue sources.
First-half performance and product growth
As reported by London Stock Exchange, citing London Stock Exchange Regulatory News Service, Shield Therapeutics releases unaudited interim results showing group revenue of $30.4 million for H1 2026, up 42% from $21.4 million a year earlier. Group loss narrows to $2.3 million from $9.5 million in H1 2025.ACCRUFeR revenue reaches $20.1 million, rising 5% from $19.2 million in the prior-year period. The company says about 102,000 ACCRUFeR prescriptions are sold in H1 2026, compared with about 84,000 in H1 2025, reflecting continued commercialization progress in the U.S.
Profitability outlook and market expansion
Shield says it remains on track for operating profitability in 2026 as it continues to build its commercial position in iron deficiency treatment. The company adds that it is focused on expanding relationships further to address unmet patient needs across multiple markets.The group also says patient indication extensions are secured in the U.S. and Europe, contributing to revenue through milestone payments and royalties. Those additions broaden the product's reach while supporting the company's revenue mix beyond core prescription growth.
Our earlier coverage of TJX Companies’ fiscal Q2 results focused on the retailer’s higher revenue and earnings alongside softer performance in its Marmaxx division that weighed on the stock. We also noted the role of tariff refunds in supporting results, as well as management’s guidance and plans to accelerate store openings while expecting trends to improve into the holiday season.
Latest Johnson & Johnson News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
